The Pharma Letter

Polpharma Biologics’ Entyvio biosimilar accepted for FDA, EMA review

Privately-held Swiss firm Polpharma Biologics says the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review regulatory filings for PB016, its proposed ...

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application ...
Nasdaq

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...
Nasdaq

FDA Approves Subcutaneous Administration Of Takeda's Entyvio For Crohn's Disease

(RTTNews) - Takeda (TAK) said that the U.S. Food and Drug Administration has approved Entyvio (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately to severely ...
Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Seeking Alpha

Alvotech gains on FDA acceptance of Entyvio biosimilar BLA

Alvotech (ALVO) shares rose in premarket trading on Monday after the company said the U.S. Food and Drug Administration accepted for review its Biologics License Application for AVT16, a proposed ...
Yahoo Finance

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monthly Prescribing Reference

Entyvio for Subcutanous Administration Approved for Ulcerative Colitis

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...
Yahoo Finance

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

"With the FDA approval of subcutaneous ENTYVIO, patients and physicians who want ENTYVIO’s clinical profile along with flexibility of administration now have two choices for maintenance treatment for ...